Literature DB >> 34964250

Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders.

Elizabeth R Stremke1,2, Laurie Trevino2, Simit Doshi3, Ranjani N Moorthi3, Kathleen M Hill Gallant1,4, Sharon M Moe2,3,5.   

Abstract

BACKGROUND: Studies evaluating the change in serum phosphate post hemodialysis (HD) demonstrate an initial decline during dialysis but a rebound post dialysis. However, previous studies were done on usual diet and phosphate binders, with limited number of blood draws, confounding conclusions. We determined serum phosphate reduction, rebound, and equilibrium over 48 h in HD patients consuming a controlled, low phosphorus diet without binders.
METHODS: Serum phosphate (mg/dL) was analyzed before and after a HD treatment and frequently during the ensuing 48 h intradialytic period in the clinical research unit. Thirteen subjects were enrolled and had been off phosphate binders for 10 days and consumed a standardized low phosphate (900 mg/day) diet for 3 weeks prior to the assessments. Linear regression was used to determine relationships between the pre-HD serum phosphate, decline post-HD (post-HD drop); and a 48 h area under curve (AUC) using the trapezoidal method as a measure of overall phosphate levels from the end of dialysis to 48 h post dialysis. Repeated Measures ANOVA with Dunnett's posthoc test was used to determine rebound.
RESULTS: Five of 13 subjects returned to >90% of their pre-HD serum phosphate within the first 24 h post-HD, and serum phosphate was 94 ± 0.11% (range 63%-113%) by 48 h after the completion of HD. The 48 h AUC of serum phosphate during the interdialytic period was correlated with both pre dialysis phosphorus (r = 0.85; p = 0.0002) and the pre-post drop in serum phosphate during dialysis (r = 0.69; p = 0.0085). In contrast, the net ultrafiltration was not related to the 48 h AUC of serum phosphorus (r = 0.20; p = 0.51).
CONCLUSIONS: In hemodialysis patients on standard low phosphorus diet and no phosphate binders, the interdialytic serum phosphorus level, assessed as AUC, is determined by the pre dialysis phosphorus and net-change in serum phosphorus during the dialysis treatment, but not the ultrafiltration volume [Correction added on 25 January, after first online publication: In the last sentence of the Abstract, the word "potassium" has been replaced with "phosphorus" to improve accuracy.].
© 2021 International Society for Hemodialysis.

Entities:  

Keywords:  diet; hemodialysis; phosphorus

Mesh:

Substances:

Year:  2021        PMID: 34964250      PMCID: PMC9096807          DOI: 10.1111/hdi.12999

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.543


  32 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

2.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

3.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2017-06-21

Review 4.  Control of hyperphosphatemia among patients with ESRD.

Authors:  Joseph A Coladonato
Journal:  J Am Soc Nephrol       Date:  2005-11       Impact factor: 10.121

5.  Dynamic behavior of plasma phosphate in chronic dialysis patients.

Authors:  H Sugisaki; M Onohara; T Kunitomo
Journal:  Trans Am Soc Artif Intern Organs       Date:  1982

Review 6.  Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake.

Authors:  Jaime Uribarri
Journal:  Semin Dial       Date:  2007 Jul-Aug       Impact factor: 3.455

7.  EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.

Authors:  Kathleen M Hill Gallant; Elizabeth R Stremke; Laurie L Trevino; Ranjani N Moorthi; Simit Doshi; Meryl E Wastney; Nozomi Hisada; Jotaro Sato; Yoshitaka Ogita; Naohisa Fujii; Yuya Matsuda; Takei Kake; Sharon M Moe
Journal:  Kidney Int       Date:  2020-10-31       Impact factor: 10.612

8.  Phosphorus Consumption Within 1 Hour Prior to Blood Work and Associated Serum Levels of Phosphate, Calcium, and PTH in Adult Patients Receiving Hemodialysis Treatment.

Authors:  Tom Mazzetti; Wilma M Hopman; Laura Couture; Erin Christilaw; Jenny Munroe; Corinne S Babiolakis; Michael A Adams; Rachel M Holden
Journal:  Can J Kidney Health Dis       Date:  2019-06-27

9.  The Impact of Normal Range of Serum Phosphorus on the Incidence of End-Stage Renal Disease by A Propensity Score Analysis.

Authors:  Wen Xiu Chang; Ning Xu; Takanori Kumagai; Takeshi Shiraishi; Takahiro Kikuyama; Hiroki Omizo; Kazuhiro Sakai; Shigeyuki Arai; Yoshifuru Tamura; Tatsuru Ota; Shigeru Shibata; Yoshihide Fujigaki; Zhong Yang Shen; Shunya Uchida
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

10.  Phosphate control in reducing FGF23 levels in hemodialysis patients.

Authors:  Cristian Rodelo-Haad; Maria E Rodríguez-Ortiz; Alejandro Martin-Malo; M Victoria Pendon-Ruiz de Mier; M Luisa Agüera; Juan R Muñoz-Castañeda; Sagrario Soriano; Francisco Caravaca; M Antonia Alvarez-Lara; Arnold Felsenfeld; Pedro Aljama; Mariano Rodriguez
Journal:  PLoS One       Date:  2018-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.